摘要:
The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.
摘要:
The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
摘要:
The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors.
摘要:
Compositions containing one or more early polypeptide(s) of human papillomavirus (HPV)-18 or a nucleic acid encoding one or more early polypeptide(s) of HPV-18 are useful for preventing or treating an infection or a pathological condition caused by at least one papillomavirus other than HPV-18; the subject compositions are of very special interest in immunotherapy, in particular for preventing or treating HPV persistent infections that might promote cervical intraepithelial neoplasia (CIN) and ultimately cervical cancer.
摘要:
La présente invention concerne des produits de combinaison comprenant (i) au moins une substance capable d'inhiber l'activité de CSF-1 et/ou au moins un acide nucléique, comprenant au moins une séquence codant pour une substance capable d'inhiber l'activité de CSF-1 et (ii) au moins une substance ayant une activité cytotoxique et/ou au moins un acide nucléique, comprenant au moins une séquence codant pour une substance ayant une activité cytotoxique. La présente invention concerne également des oligonucléotides capables d'inhiber l'expression de CSF-1. La présente invention est particulièrement utile dans le cadre de la mise en oeuvre d'un traitement antitumoral.
摘要:
The invention concerns a recombinant adenoviral vector driving from an adenovirus genome at least by deleting all or part of the E1 region, said adenoviral vector comprising an expression cassette of a gene of interest placed under the control of elements necessary for its expression in a host cell or a host organism, said elements required for its expression including at least a splicing sequence. The invention is characterised in that said splicing sequence is derived from a eukaryotic nuclear gene selected among the ovalbumen genes, α or β-globine, collagen and factor VIII of mammals or a synthetic splicing sequence. The invention also concerns a host cell and an infectious viral particle comprising such a vector, a method for preparing such a particle and their therapeutic or prophylactic use. The invention further concerns a pharmaceutical composition containing said adenoviral vector, said host cell or said viral particle.
摘要:
The invention concerns a biological organism comprising at least: (i) a nucleic acid coding for all or part of an antibody, said antibody being expressed at the surface of a host cell and capable of being fixed to a polypeptide present at the surface of a cytotoxic effector cell or of a T-helper lymphocyte and involved in the process of activating such a cell and (ii) a nucleic acid coding for all or part of a polypeptide involved in the stimulation of an immune response or in attraction to the site of expression and activation of cytotoxic effector cells or of T-helper lymphocytes, said polypeptide being selected among chemokines and co-stimulation molecules. The invention also concerns a host cell and a pharmaceutical composition containing said biological organism and their therapeutic or prophylactic uses.
摘要:
The present invention relates to targeting peptides and more specifically peptides that target heart and various tumors as well as to their use for targeting. The present invention also provides a composition comprising at least one therapeutic agent and at least one peptide of the invention or, alternatively, a nucleic acid molecule encoding such a peptide as well as its use for the preparation of a drug intended for gene transfer.
摘要:
The invention concerns an adenovirus fibre modified by mutation of one or several residues of the region included between residues 491 and 505 of SEQ ID NO: 1, the viral particles or pseudo-particles comprising such a fibre and their uses.